Loading...
•
Mar 31, 2024
ADMA Biologics Q1 2024 Earnings Report
ADMA Biologics surpassed financial expectations and delivered earnings growth in Q1 2024.
Key Takeaways
ADMA Biologics reported a strong first quarter in 2024, marked by a 44% increase in total revenue, achieving $81.9 million. The company's net income reached $17.8 million, and adjusted EBITDA was $26.4 million, reflecting significant year-over-year growth and leading to increased financial guidance for 2024 and 2025.
Total revenue for Q1 2024 reached $81.9 million, a 44% increase year-over-year.
GAAP net income for Q1 2024 was $17.8 million, a $24.6 million increase year-over-year.
Adjusted EBITDA for Q1 2024 was $26.4 million, a 970% increase year-over-year.
FY 2024 and 2025 total revenue and net income guidance were increased.
Forward Guidance
ADMA Biologics increased its financial guidance for fiscal years 2024 and 2025, expecting higher total revenue, net income, and adjusted EBITDA.
Positive Outlook
- FY 2024 total revenue is expected to be more than $355 million.
- FY 2025 total revenue is expected to be more than $410 million.
- FY 2024 net income is expected to exceed $85 million.
- FY 2025 net income is expected to exceed $135 million.
- FY 2024 Adjusted EBITDA is anticipated to exceed $110 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...